Anitha Thambiayyan
Research Subjects
Anitha Thambiayyan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Madhumitha Chidambaram
Department of Computer Science and Engineering, Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology, Chennai, India
1 shared publication - Sathiya Priya Selvaraj
Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University,Department of Computer Science Engineering,Chennai,India
1 shared publication - Sathya Velusamy
Department of Information Technology, Velammal Engineering College, Surapet, Chennai
1 shared publication - Usha Velusamy
Department of Computer Science and Engineering, Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology, Chennai, India
1 shared publication - Vinodhini Kanakaraj
Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology Avadi
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 1 (19) , 386-397
Scorpi-XStack: Improving Type 2 Diabetes Prediction via Feature Optimization and Stacking
Early detection of Type 2 Diabetes (T2D) is perilous for remediating patient consequences and dropping long-term complications. This study proposes Scorpi-XStack, a diagnostic framework that integrates a novel bio-inspired optimization algorithm, ScorpiOpt, with stacked ensemble learning to enhance predictive accuracy. ScorpiOpt identifies the most discriminative clinical features by reducing redundancy and improving feature robustness. These selected features are used to train a weighted collaborative classifier containing Random Forest and XGBoost as ignoble learners, for which Logistic Regression is the master learner. The framework was validated on three benchmark datasets—Pima Indian Diabetes (Kaggle), clinical records from Medical City Hospital, Iraq (Mendeley Data), and the Frankfurt Diabetes dataset (GitHub/ResearchGate)—after applying ETL processing, mean/mode imputation for missing values, and z-score normalization. Classical recital remained assessed via stratiform 5-fold cross-validation, springy an accurateness of 98.54%, F1-score of 98.50%, balanced accuracy of 98.52% and AUROC of 99.86%. Compared with existing methods (85–95% accuracy range), Scorpi-XStack demonstrated consistent improvements across multiple performance metrics. While results are promising, limitations such as dataset heterogeneity, potential overfitting, and computational overhead should be noted. Further validation on larger, independent, and multi-center cohorts is necessary to confirm clinical applicability and generalizability.
- 20 March 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 1 (19) , 386-397
Open AccessScorpi-XStack: Improving Type 2 Diabetes Prediction via Feature Optimization and Stacking
Early detection of Type 2 Diabetes (T2D) is perilous for remediating patient consequences and dropping long-term complications. This study proposes Scorpi-XStack, a diagnostic framework that integrates a novel bio-inspired optimization algorithm, ScorpiOpt, with stacked ensemble learning to enhance predictive accuracy. ScorpiOpt identifies the most discriminative clinical features by reducing redundancy and improving feature robustness. These selected features are used to train a weighted collaborative classifier containing Random Forest and XGBoost as ignoble learners, for which Logistic Regression is the master learner. The framework was validated on three benchmark datasets—Pima Indian Diabetes (Kaggle), clinical records from Medical City Hospital, Iraq (Mendeley Data), and the Frankfurt Diabetes dataset (GitHub/ResearchGate)—after applying ETL processing, mean/mode imputation for missing values, and z-score normalization. Classical recital remained assessed via stratiform 5-fold cross-validation, springy an accurateness of 98.54%, F1-score of 98.50%, balanced accuracy of 98.52% and AUROC of 99.86%. Compared with existing methods (85–95% accuracy range), Scorpi-XStack demonstrated consistent improvements across multiple performance metrics. While results are promising, limitations such as dataset heterogeneity, potential overfitting, and computational overhead should be noted. Further validation on larger, independent, and multi-center cohorts is necessary to confirm clinical applicability and generalizability.